Jamie Hirata

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 772 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Medicine, Immunology, Oncology +14

Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study

Jonathan W. Friedberg, Michelle Byrtek, Brian K. Link et al. · Journal of Clinical Oncology · 2012 · 178 citations · Full text

Medicine, Hematology, Oncology +17

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Laurie H. Sehn, Mark Hertzberg, Stephen Opat et al. · Blood Advances · 2021 · 177 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett et al. · The Lancet Oncology · 2019 · 139 citations · Full text

Medicine, Immunology, Oncology +9